Overview

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This study will determine whether the association of Revlimid and Prednisone (RP) as induction treatment followed by Revlimid, Melphalan and Prednisone (MPR) as consolidation treatment is safe and induce a significant rate of PR (and CR) in newly diagnosed elderly MM patients.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione EMN Italy Onlus
Fondazione Neoplasie Sangue Onlus

Treatments:

Lenalidomide
Melphalan
Prednisone